Who Cannot Take Wegovy, and What to Check Before Applying

The conditions that rule Wegovy out entirely

A small number of situations represent hard stops. Wegovy must not be prescribed to anyone with a personal or family history of medullary thyroid carcinoma, a rare cancer of the thyroid gland, or to anyone with Multiple Endocrine Neoplasia syndrome type 2, a genetic condition that raises the risk of that same cancer. These contraindications exist because semaglutide has been shown to cause thyroid tumours in animal studies, and although a direct human risk has not been established, the caution is absolute in UK clinical practice. The Wegovy overview page sets this in context alongside how the medicine works.

Anyone who has had acute pancreatitis in the past, or who has a chronic condition significantly affecting the gastrointestinal tract, will face close scrutiny. Prescribers are guided by the NHS patient information for semaglutide, which lists severe allergic reaction to semaglutide or any of its ingredients as another absolute contraindication. If you have had a reaction to a GLP-1 medicine before, tell your prescriber before any application.

Pregnancy sits in its own category. Wegovy is not recommended during pregnancy, while breastfeeding, or when trying to conceive. Women of childbearing age are advised to use effective contraception throughout treatment. Before stopping Wegovy with the intention of becoming pregnant, your prescriber will discuss an appropriate wash-out period, this is a conversation for the consultation, not a figure to look up independently.

Cautions that need a prescriber's judgement, not a flat refusal

Beyond the clear contraindications, there is a broader group of medical situations where Wegovy may still be suitable but needs more careful thought. Diabetic retinopathy (damage to the blood vessels at the back of the eye) is one of them. Rapid improvements in blood glucose can sometimes cause a temporary worsening of retinopathy, so anyone with this diagnosis warrants a discussion about monitoring. Similarly, people with severe kidney disease or a history of heart failure should have these conditions factored into the prescribing decision. Neither automatically rules out treatment, but neither can be ignored.

People who take medicines with a narrow therapeutic window (meaning the dose has to be just right to be effective and safe) need particular attention, because Wegovy slows how quickly food and other medicines move through the stomach. This can alter the absorption of some oral drugs. If you take warfarin, for example, your INR may need closer monitoring when you start treatment. Your prescriber will review your full medicines list, including anything bought over the counter. If you are already exploring your options, the semaglutide eligibility guide covers the positive side of this picture in more detail.

Eating disorders (both current and historical) are another area where clinicians apply careful judgement. GLP-1 medicines have a strong appetite-suppressing effect, and that can interact in complex ways with a person's relationship with food. This is not a blanket disqualifier, but it is something to discuss openly. If you have concerns in this area, the team at Beat, the eating disorder charity, offers support independent of any treatment decision.

Who is outside the licensed age and BMI thresholds

Wegovy's UK licence covers adults only. It is not approved for anyone under 18, and no reputable UK prescriber will supply it to a minor. Age is straightforward to establish; BMI eligibility requires a little more checking. The licence sets BMI at 30 kg/m² or above, or at 27–29.9 with at least one weight-related health condition such as high blood pressure, type 2 diabetes, raised cholesterol or obstructive sleep apnoea. If your BMI sits below these thresholds, the medicine is not currently licensed for you regardless of other factors. You can get an accurate reading in about thirty seconds using the NHS BMI calculator, which is useful to do before a consultation. The BMI requirements for Wegovy page goes into the thresholds in full, including the adjustments that apply for some ethnic backgrounds under UK guidance. That adjustment is worth reading if it may apply to you.

If you are not sure where you stand, our page covering who is eligible for Wegovy sets out the criteria clearly, and reading it alongside the can I take Wegovy guide gives you the most complete picture before speaking to a prescriber.

What to do if you are not sure

The honest answer is: check with a prescriber. Contraindication lists are designed for clinical practice, where a qualified person reads the full picture, not just a diagnosis, but its severity, its treatment, and how it interacts with everything else going on for you. Reading this page can help you arrive at a consultation informed and ready, but it cannot substitute for that review. At nume, a GPhC-registered Independent Prescriber reads every consultation personally. No automated approvals, no algorithm making the call. If Wegovy is not suitable, the prescriber will say so clearly and explain why, that outcome, though disappointing, is a safety system working as it should. You can see how our clinical team approaches these decisions on the clinical team page, and if you have questions before starting, the FAQs cover the most common ones. When you are ready, check your eligibility through a free consultation.